Search
Risankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Betamethasone
go.drugbank.com/drugs/DB00443ApprovedInvestigationalVet approvedBetamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states inclu...
Mixtures: Lotrisone, LotrisoneProducts: PHEX-BESILLumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigationalLumacaftor is a drug used in combination with DB08820 as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused ...
Butriptyline
go.drugbank.com/drugs/DB09016ApprovedWithdrawnButriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.
Inositol nicotinate
go.drugbank.com/drugs/DB08949ApprovedWithdrawnInositol nicotinate is prescribed in Europe under the name Hexopal as a symptomatic treatment for severe intermittent claudication and Raynaud’s phenomenon.
Befunolol
go.drugbank.com/drugs/DB09013ExperimentalIt is currently in experimental status, and is being tested for the management of open angle glaucoma.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Protokylol
go.drugbank.com/drugs/DB06814ApprovedVet approvedProtokylol is a β-adrenergic receptor agonist used as a bronchodilator in Europe and the United States.
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalTalc is a mineral composed primarily of magnesium, silicon and oxygen. It is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. Talc helps absorb moisture, fres...
Camizestrant
go.drugbank.com/drugs/DB19218ApprovedInvestigational[L64094,L64107] It binds the ligand binding domain of ERα, antagonizing ERα encoded by both wild-type and mutated *ESR1* and inducing proteasome-dependent degradation of the receptor without agonizing … [L64094,L64107] The European Commission approved camizestrant on July 23, 2026, Health Canada authorized it on August 4, 2026, and the FDA granted accelerated approval on September 4, 2026.